WO2025169047 - IMPROVED PRODUCTION OF ANGPTL3 MIMETICS
National phase entry is expected:
Publication Number
WO/2025/169047
Publication Date
14.08.2025
International Application No.
PCT/IB2025/051119
International Filing Date
03.02.2025
Title **
[English]
IMPROVED PRODUCTION OF ANGPTL3 MIMETICS
[French]
PRODUCTION AMÉLIORÉE DE MIMÉTIQUES D'ANGPTL3
Applicants **
NOVARTIS AG
Inventors
AEHLE, Mathias
AUSLAENDER, David
HARDANK, Katrin
LEBESGUE, Nicolas
OBRDLIK, Petr
SAUER, Dominik Georg
TAPPAREL, Joël Aloïs René
WAGNER, Nina
Priority Data
63/549,658
05.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2717 | |
| EPO | Filing, Examination, Granting | 15571 | |
| Japan | Filing, Examination, Granting | 2524 | |
| South Korea | Filing, Examination, Granting | 2818 | |
| USA | Filing, Examination, Granting | 6740 |
Total:
30,370
Contact Us
Abstract[English]
The present invention pertains to the use of gene editing and miRNA technologies for improving recombinant production of ANGPTL3 mimetics in CHO cells. The gene expression modifications are used for knock-out/knock-down of the endogenous protein CCL2 of the CHO cells which is difficult to separate from ANGPTL3 mimetics during purification.[French]
La présente invention concerne l'utilisation de technologies d'édition de gènes et de miARN pour améliorer la production recombinante de mimétiques d'ANGPTL3 dans des cellules CHO. Les modifications d'expression génique sont utilisées pour inactiver/inactiver la protéine endogène CCL2 des cellules CHO qui est difficile à séparer des mimétiques d'ANGPTL3 pendant la purification.